Gleneagle Securities is pleased to advise that we will start to provide our Blog subscribers with access to exclusive investor presentations. Our first video conference is with Henry Charrabé (CEO of Fluence Corporation, FLC.ASX) on Tuesday 19th March at 8:45am.
Please 
for the dial-in details.
At the meeting we will discuss with Fluence’s business model, where they are seeing growth, how they are positioned in the market and highlight recent project wins which are helping to underscore their goal of reaching sustainable EBITDA profitability by Q4 in 2019.
Fluence has a current market capitalisation of ~$200m and has been listed since July 2017 when RWL Water and Emefcy merged. This merger brought together technological and operational expertise allowing them to realistically target global leadership in decentralised water and wastewater solutions.
Fluence manufacture and sell IP rich Smart Product Solutions which treat wastewater 80% more efficiently and at a lower cost than competitor solutions and containerised desalination units that are quick to deploy. Other bespoke solutions have been developed for use in industry and larger custom-engineered solutions are also a part of the business mix. As an example in February this year Fluence signed a €165M commercial agreement with Federal Government of Ivory Coast to provide potable water to Abidjan, the country’s largest city.
The need for clean water is universal and Fluence is a global business whose innovative products are gaining increasing recognition and acceptance in the market. This is evidenced by organic growth in revenue by 74% last year to US$101.1m while also seeing a >2x increase in gross profit to $34.5m. The business is structured to grow and there remains an enormous opportunity for Fluence as it executes on its growth ambitions.
The chart below supports the fundamentals above to indicate a good entry point by showing a strong base at these levels
Please contact us for further queries or subscribe (on the right of this page) to receive further updates.